Safety and PK of Subcutaneous GS-6207, a Novel HIV-1 Capsid Inhibitor

Slides:

Advertisements

Similar presentations

Pilot and Pharmacokinetic Studies of Solubilized Estradiol Administered Vaginally in a Softgel Capsule James H. Pickar, M.D., F.A.C.O.G.

Advertisements

TMC278 Update, 30th January 2009  C204 data  ECHO and THRIVE - Phase III studies  New TMC278 formulations Peter Williams Tibotec BVBA, Mechelen, Belgium.

Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis Karel de Beule, CDTL.

Phase Difference = Phase Difference = 0.05.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

FDA Nasal BA/BE Guidance Overview

Acknowledgement We would like to thank ORSP for funding. Acknowledgement We would like to thank ORSP for funding. Introduction Mice are nocturnal animals.

IEEE 64 th ECTC – Orlando, FL, USA May 27–30, 2014 Add Company Logo Here.

C-IN- 1 Raptiva ™ (efalizumab) Introduction Michelle Rohrer, PhD Director Regulatory Affairs Genentech, Inc.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

Enfuvirtide for Drug-Resistant HIV Infection in North and South America Simon R. Bababeygy.

Vaccines and Related Biological Products Advisory Committee Meeting Hepatitis B Vaccine (Recombinant), Adjuvanted (HEPLISAV): Review of Immunogenicity.

WEEK 1 You have 10 seconds to name…

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.

Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health.

Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.

THREE COLUMN (Click to edit) Introduction or Abstract Type in or past your text (Click to edit) Materials and Methods Type in or past your text (Click.

BSA 375 Week 1 Individual Software Development Presentation Create an annotated or narrated 7- to 10-slide presentation that includes the following: An.

What’s Next – and When: An Update on Injectable Prevention

What a Thesis Statement Does

Materials & Methods Introduction Abstract Results Conclusion

References & Acknowledgements

Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Visit for more Information: %284PK%29+-+New+Compatible+Inkjet+Cartridges.

Darunavir/r versus Other PIs in Treatment Experienced POWER 1 and 2

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Materials & Methods Introduction Abstract Results Conclusion

Metastatic Renal Cell Carcinoma

خشنه اتره اهورهه مزدا شيوۀ ارائه مقاله 17/10/1388.

FEM 4204 INDIVIDUAL/GROUPWORK ASSIGNMENT (20%)

Extended Half-life Factor Products in the Management of Hemophilia

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic.

Novel Small Molecule Therapies in Rheumatoid Arthritis

Treating HIV Infection:

مدیریت امور آزمایشگاهها دانشگاه علوم پزشکی کاشان

P O S T E R T I T L E Authors & Institutions

Put your name here Name of the Department, School or College

Faster-Acting Insulins

Is it Time for a Paradigm Change in HIV Management?

Individualizing Factor Replacement Therapy for Patients With Hemophilia.

Introduction Results Conclusions Methods & Materials References

Issues in the Management of Hemophilia: A Best Practice Series

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Abstract Methods & Materials Results cont. Conclusion Introduction

The Evolving Treatment Landscape in Atopic Dermatitis

University/Department / Faculty (Arial Bold 28-32)

Canadian Association of Nuclear Medicine

Extended Half-life Factor Products in the Management of Hemophilia

How to Manage ISRs That Occur With Injectable Agents in Psoriasis

Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects Akizawa et.

Materials & Methods Introduction Abstract Results Conclusion

Poster Title: Background and Introduction Methods and Results

Abstract Materials & Methods Results Conclusion Introduction

Materials & Methods Introduction Abstract Results Conclusion

Research Paper Overview.

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?

Real-World Evidence.

Student Name Student College Student Department Submission No:

Title Presenter name DATE Towards a More Sustainable World.

Introduction. Activation of HIV-Specific CD8+ T Cells from HIV+ Donors by Vesatolimod.

Materials & Methods Introduction Abstract Results Conclusion

Rheumatoid Arthritis.

Student Name (VU ID…) MS in ………..

LEARNING & DEVELOPMENT STRATEGY: PROCESS OVERVIEW

A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects by Naoki Uchida, Takehiko Sambe, Koichiro.

Materials & Methods Introduction Abstract Results Conclusion

Safety and Antiviral Activity Over 10 Days Following a Single Dose of Subcutaneous GS-6207, a First-in-Class, Long-Acting HIV Capsid Inhibitor in People.

Presentation transcript:

Safety and PK of Subcutaneous GS-6207, a Novel HIV-1 Capsid Inhibitor

Disclosure

Acknowledgements

Introduction

GS-6207: First-in-Class HIV Capsid Inhibitor

GS-6207: First-in-Class HIV Capsid Inhibitor

GS-6207: Overview

GS-6207 First-In-Human Phase 1 Study

GS-6207 First-In-Human Phase 1 Study: Methods

Results Subject Enrollment and Demographics

Results Safety

Results Sustained GS-6207 Exposure Following Subcutaneous Injection

Results Sustained GS-6207 Exposure Following Subcutaneous Injection

Results Sustained Delivery Supports Dosing Interval of at least 12 Weeks

Conclusions